New perspectives on the use of mTOR inhibitors in allogeneic haematopoietic stem cell transplantation and graft‐versus‐host disease

Repertoires of Autophagy in the Pathogenesis of Ocular Diseases

Li, Y., Jiang, Q. L., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,351 · see citing works

TOR signaling in growth and metabolism

Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787 · see citing works

mTOR: from growth signal integration to cancer, diabetes and ageing

Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941 · see citing works

Defining the role of mTOR in cancer

Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833 · see citing works

The PI3K Pathway As Drug Target in Human Cancer

Courtney, K. D., Corcoran, R. B., & Engelman, J. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3641 · Cited by 1,235 · see citing works

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey

Zeiser, R., Burchert, A., Lengerke, C., Verbeek, M., Maas‐Bauer, K., Metzelder, S., Spoerl, S., Ditschkowski, M., Ecsedi, M., Sockel, K., et al. (2015) · Leukemia · doi:10.1038/leu.2015.212 · Cited by 538 · see citing works

SDZ RAD, A NEW RAPAMYCIN DERIVATIVE

Schüler, W., Sedrani, R. C., Cottens, S., berlin, B. H., Schulz, M., Schuurman, H., Zenke, G., Zerwes, H., & Schreier, M. H. (1997) · Transplantation · doi:10.1097/00007890-199707150-00008 · Cited by 534 · see citing works

<scp>mTOR</scp> , metabolism, and the regulation of T‐cell differentiation and function

Waickman, A. T., & Powell, J. D. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01152.x · Cited by 420 · see citing works

Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease

Wolff, D., Schleuning, M., von Harsdorf, S., Bacher, U., Gerbitz, A., Stadler, M., Ayuk, F. A., Kiani, A., Schwerdtfeger, R., Vogelsang, G. B., et al. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.05.011 · Cited by 327 · see citing works

Antileukemic activity of rapamycin in acute myeloid leukemia

Récher, C., Beyne‐Rauzy, O., Demur, C., Chicanne, G., Santos, C. D., Mas, V. M., Benzaquen, D., Laurent, G., Huguet, F., & Payrastre, B. (2004) · Blood · doi:10.1182/blood-2004-06-2494 · Cited by 296 · see citing works

PI3K/Akt/mTOR inhibitors in breast cancer.

Lee, J. J. X., Loh, K. W.-J., & Yap, Y. S. (2015) · Europe PMC (PubMed Central) · doi:10.7497/j.issn.2095-3941.2015.0089 · Cited by 230 · see citing works

Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT

Cutler, C. S., Logan, B. R., Nakamura, R., Johnston, L., Choi, S. W., Porter, D., Hogan, W. J., Pasquini, M. C., MacMillan, M. L., Hsu, J. W., et al. (2014) · Blood · doi:10.1182/blood-2014-04-567164 · Cited by 224 · see citing works

Sjögren-Type Syndrome After Allogeneic Bone-Marrow Transplantation

GRATWHOL, A. A., MOUTSOPOULOS, H. M., CHUSED, T. M., AKIZUKI, M., WOLF, R. O., SWEET, J. B., & DEISSEROTH, A. B. (1977) · Annals of Internal Medicine · doi:10.7326/0003-4819-87-6-703 · Cited by 214 · see citing works

Everolimus and sirolimus in transplantation-related but different

Klawitter, J., Nashan, B., & Christians, U. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1040388 · Cited by 187 · see citing works

SIROLIMUS (RAPAMYCIN) FOR THE TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE1

Benito, A. I., Furlong, T., Martin, P. J., Anasetti, C., Appelbaum, F. R., Doney, K., Nash, R. A., Papayannopoulou, T., Storb, R. F., Sullivan, K. M., et al. (2001) · Transplantation · doi:10.1097/00007890-200112270-00010 · Cited by 185 · see citing works

Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft‐versus‐host disease

Couriel, D. R., Saliba, R. M., Escalón, M. P., Hsu, Y., Ghosh, S., Ippoliti, C. M., Hicks, K. L., Donato, M. L., Giralt, S. A., Khouri, I. F., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05616.x · Cited by 185 · see citing works

PI3K/Akt/mTOR inhibitors in breast cancer

Joycelyn, Jx, Lee, Kiley, Loh, K. W.-J., Yoon-Sim, & Yap (2015) · 癌症生物学与医学：英文版 · Cited by 185 · see citing works

Everolimus Initiation and Early Calcineurin Inhibitor Withdrawal in Heart Transplant Recipients: A Randomized Trial

Andreassen, A. K., Andersson, B., Gustafsson, F., Eiskjær, H., Rådegran, G., Gude, E., Jansson, K., Solbu, D., Sigurdardottir, V., Arora, S., et al. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12809 · Cited by 157 · see citing works

Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation

Antin, J. H., Kim, H. T., Cutler, C. S., Ho, V. T., Lee, S. J., Miklos, D. B., Hochberg, E. P., Wu, C. J., Alyea, E. P., & Soiffer, R. J. (2003) · Blood · doi:10.1182/blood-2003-02-0489 · Cited by 153 · see citing works

Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis

Marty, F. M., Porter, J., Browne, S., Schwarzberg, T., Ho, V. T., Bassett, I. V., Koreth, J., Alyea, E. P., Soiffer, R. J., Cutler, C. S., et al. (2007) · Blood · doi:10.1182/blood-2007-01-069294 · Cited by 142 · see citing works

Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells

Cieri, N., Greco, R., Crucitti, L., Morelli, M., Giglio, F., Levati, G. V., Assanelli, A. A., Carrabba, M. G., Bellio, L., Milani, R., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.04.025 · Cited by 141 · see citing works

Tacrolimus-Associated Posterior Reversible Encephalopathy Syndrome after Solid Organ Transplantation

Wu, Q., Marescaux, C., Wolff, V., Jeung, M., Kessler, R., Lauer, V., & Chen, Y. (2010) · European Neurology · doi:10.1159/000319032 · Cited by 132 · see citing works

Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease

Johnston, L., Brown, J. W., Shizuru, J. A., Stockerl-Goldstein, K. E., Stuart, M. J., Blume, K. G., Negrin, R. S., & Chao, N. J. A. (2004) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2004.10.004 · Cited by 131 · see citing works

The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children’s Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial

Pulsipher, M. A., Langholz, B. M., Wall, D. A., Schultz, K. R., Bunin, N., Carroll, W. L., Raetz, E. A., Gardner, S. L., Gastier, J. M., Howrie, D. L., et al. (2014) · Blood · doi:10.1182/blood-2013-10-534297 · Cited by 127 · see citing works

Sirolimus and everolimus in kidney transplantation

Moes, D. J. A. R., Guchelaar, H., & de Fijter, J. W. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.05.006 · Cited by 126 · see citing works

Improved Survival in Lymphoma Patients Receiving Sirolimus for Graft-Versus-Host Disease Prophylaxis After Allogeneic Hematopoietic Stem-Cell Transplantation With Reduced-Intensity Conditioning

Armand, P. A., Gannamaneni, S., Kim, H. T., Cutler, C. S., Ho, V. T., Koreth, J., Alyea, E. P., LaCasce, A. S., Jacobsen, E. D., Fisher, D. C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7279 · Cited by 114 · see citing works

mTOR and lymphocyte metabolism

Zeng, H., & Chi, H. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.05.002 · Cited by 101 · see citing works

A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation

Pidala, J., Kim, J., Jim, H., Kharfan‐Dabaja, M. A., Nishihori, T., Fernandez, H. F., Tomblyn, M. R., Perez, L. E., Perkins, J. B., Xu, M., et al. (2012) · Haematologica · doi:10.3324/haematol.2012.067140 · Cited by 98 · see citing works

Targeting the mTOR Signaling Pathway in Neuroendocrine Tumors

Chan, J. A., & Kulke, M. H. (2014) · Current Treatment Options in Oncology · doi:10.1007/s11864-014-0294-4 · Cited by 91 · see citing works

Sirolimus for treatment of steroid-refractory acute graft-versus-host disease

Hoda, D., Pidala, J., Salgado-Vila, N., Kim, J., Perkins, J. B., Bookout, R., Field, T. L., Perez, L. E., Ayala, E., Ochoa-Bayona, J. L., et al. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.343 · Cited by 76 · see citing works

The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence

Klintmalm, G. B. G., & Nashan, B. (2014) · Journal of Transplantation · doi:10.1155/2014/845438 · Cited by 76 · see citing works

The use of sirolimus in ganciclovir‐resistant cytomegalovirus infections in renal transplant recipients

Ozaki¹, K. S., Câmara, N. O. S., Nogueira, E., Pereira, M. G., Granato, C. F. H., Melaragno, C. S., Camargo, L. F. A., & Pacheco‐Silva, Á. (2007) · Clinical Transplantation · doi:10.1111/j.1399-0012.2007.00699.x · Cited by 72 · see citing works

Calcineurin Inhibitor–Free Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide and Brief-Course Sirolimus Following Reduced-Intensity Peripheral Blood Stem Cell Transplantation

Solomon, S. R., Sanacore, M., Zhang, X., Brown, S. L., Holland, K., Morris, L. E., & Bashey, A. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.07.020 · Cited by 66 · see citing works

Sirolimus as Part of Immunosuppressive Therapy for Refractory Chronic Graft-versus-Host Disease

Jurado, M., Vallejo, C. T., Pérez‐Simón, J. A., Brunet, S., Ferra, C. M., Balsalobre, P., de Oteyza, J. P., Espigado, I., Romero, A., Caballero, D. M., et al. (2007) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2007.02.003 · Cited by 63 · see citing works

The addition of sirolimus to the graft‐versus‐host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial

Armand, P. A., Kim, H. T., Sainvil, M.-M., Lange, P. B., Giardino, A. A., Bachanová, V., Devine, S. M., Waller, E. K., Jagirdar, N., Herrera, A. F., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.13931 · Cited by 57 · see citing works

Defining the Role of Sirolimus in the Management of Graft-versus-Host Disease: From Prophylaxis to Treatment

Abouelnasr, A., Roy, J., Cohen, S., Kiss, T. L., & Lachance, S. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.06.020 · Cited by 55 · see citing works

Graft-versus-Host disease Prophylaxis with Everolimus and Tacrolimus Is Associated with a High Incidence of Sinusoidal Obstruction Syndrome and Microangiopathy: Results of the EVTAC Trial

Platzbecker, U., Bonin, M. V., Goekkurt, E., Radke, J., Binder, M., Kiani, A., Stoehlmacher, J., Schetelig, J., Thiede, C., Ehninger, G., et al. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.11.004 · Cited by 54 · see citing works

Rapamycin Inhibits Human Laryngotracheal Stenosis–derived Fibroblast Proliferation, Metabolism, and Function in Vitro

Namba, D. R., Ma, G., Samad, I., Ding, D., Pandian, V., Powell, J. D., Horton, M. R., & Hillel, A. T. (2015) · Otolaryngology · doi:10.1177/0194599815573708 · Cited by 51 · see citing works

Calcineurin inhibitor-free GVHD prophylaxis with sirolimus, mycophenolate mofetil and ATG in Allo-SCT for leukemia patients with high relapse risk: an observational cohort study

Schleuning, M., Judith, D., Jedlickova, Z., Stübig, T., Heshmat, M., Baurmann, H., & Schwerdtfeger, R. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.377 · Cited by 51 · see citing works

High prevalence of distress in patients after allogeneic hematopoietic SCT: Fear of progression is associated with a younger age

Hefner, J., Kapp, M., Drebinger, K., Dannenmann, A., Einsele, H., Grigoleit, G.-U., Faller, H., Csef, H., & Mielke, S. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2013.228 · Cited by 50 · see citing works

Therapy of Sclerodermatous Chronic Graft-Versus-Host Disease with Mammalian Target of Rapamycin Inhibitors

Jedlickova, Z., Burlakova, I., Bug, G., Baurmann, H., Schwerdtfeger, R., & Schleuning, M. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.07.025 · Cited by 47 · see citing works

Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation

Johnston, L., Florek, M., Armstrong, R. J., McCune, J. S., Arai, S., Brown, J. W., Laport, G. G., Lowsky, R., Miklos, D. B., Shizuru, J. A., et al. (2011) · Bone Marrow Transplantation · doi:10.1038/bmt.2011.104 · Cited by 45 · see citing works

Inhibition by Rapamycin of PDGF- and bFGF-Induced Human Tenon Fibroblast Proliferation in Vitro

Salas‐Prato, M., Assalian, A., Mehdi, A. Z., Duperr, J., Thompson, P., & Brazeau, P. (1996) · Journal of Glaucoma · doi:10.1097/00061198-199602000-00009 · Cited by 43 · see citing works

Natural history, management and pharmacokinetics of Everolimus-induced-oral ulcers: Insights into compliance issues

Ferté, C., Paci, A., Zizi, M., Barrios-Gonzales, D., Goubar, A., Gomez‐Roca, C., Massard, C., Sahmoud, T., André, F., & Soria, J. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.03.017 · Cited by 43 · see citing works

Sirolimus as Primary Treatment of Acute Graft-versus-Host Disease following Allogeneic Hematopoietic Cell Transplantation

Pidala, J., Kim, J., & Anasetti, C. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2009.03.020 · Cited by 38 · see citing works

Rapamycin for Refractory Acute Graft-Versus-Host Disease

Ghez, D., Rubio, M., Maillard, N., Suárez, F., Chandesris, M., Delarue, R., Deau, B., Varet, B. R., Hermine, O., & Buzyn, A. (2009) · Transplantation · doi:10.1097/tp.0b013e3181ba0a13 · Cited by 35 · see citing works

A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation

Kornblit, B. T., Maloney, D. G., Storer, B. E., Maris, M. B., Vindeløv, L. L., Hari, P., Langston, A. A., Pulsipher, M. A., Bethge, W. A., Chauncey, T. R., et al. (2014) · Haematologica · doi:10.3324/haematol.2014.108340 · Cited by 35 · see citing works

Graft-Versus-Host Disease Prophylaxis after Transplantation: A Network Meta-Analysis

Ziakas, P. D., Zervou, F. N., Zacharioudakis, I. M., & Mylonakis, E. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114735 · Cited by 34 · see citing works

The impact ofCYP3A5*3polymorphism on sirolimus pharmacokinetics: insights from predictions with a physiologically‐based pharmacokinetic model

Emoto, C., Fukuda, T., Venkatasubramanian, R., & Vinks, A. A. T. M. M. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12743 · Cited by 32 · see citing works

Salvage therapy with everolimus reduces the severity of treatment-refractory chronic GVHD without impairing disease control: A dual center retrospective analysis

Mielke, S., Lutz, M., Schmidhuber, J., Kapp, M., Ditz, D., Ammer, J., Einsele, H., Grigoleit, G. U., Holler, E., & Wolff, D. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.170 · Cited by 26 · see citing works

Drug Interactions and the Pharmacist: Focus on Everolimus

Grabowsky, J. A. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r769 · Cited by 26 · see citing works

In vivo inhibition of cytokine responsiveness and graft-versus-host disease mortality by rapamycin leads to a clinical-pathological syndrome discrete from that observed with cyclosporin A

Blazar, B., Taylor, P. A., Panoskaltsis‐Mortari, A., Sehgal, S. N., & Vallera, D. (1996) · Blood · doi:10.1182/blood.v87.9.4001.bloodjournal8794001 · Cited by 26 · see citing works

Clinical Management of Posterior Reversible Encephalopathy Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation: A Case Series and Review of the Literature

Schmidt, V., Prell, T., Treschl, A., Klink, A., Hochhaus, A., & Sayer, H. G. (2015) · Acta Haematologica · doi:10.1159/000430489 · Cited by 25 · see citing works

Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease

Pidala, J., Kim, J., Alsina, M., Ayala, E. S. I., Betts, B. C., Fernandez, H. F., Field, T. L., Jim, H., Kharfan‐Dabaja, M. A., Locke, F. L., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.123588 · Cited by 23 · see citing works

Comorbidity burden in patients with chronic GVHD

Wood, W. A., Chai, X., Weisdorf, D. J., Martin, P. J., Cutler, C. S., Inamoto, Y., Wolff, D., Pavletic, S. Z., Pidala, J., Palmer, J. M., et al. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2013.70 · Cited by 23 · see citing works

Transplantation-Associated Thrombotic Microangiopathy in Patients Treated With Sirolimus and Cyclosporine as Salvage Therapy for Graft-Versus-Host Disease

García-Martín, P., Alarcón-Payer, C., López‐Fernández, E., Moratalla, L., Romero, A., Sáinz, J., Ríos, R., & Jurado, M. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015593369 · Cited by 23 · see citing works

Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids

Pidala, J., Tomblyn, M., Nishihori, T., Field, T. L., Ayala, E., Perkins, J. B., Fernandez, H. F., Locke, F. L., Perez, L., Ochoa, J. L., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.041236 · Cited by 21 · see citing works

The novel combination of sirolimus and bortezomib prevents graft-versus-host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation

Caballero‐Velázquez, T., Sánchez-Abarca, L. I., Gutierrez-Cosío, S., Blanco, B., Calderón, C., Herrero, C., Carrancio, S., Serrano, C. R., del Cañizo, C., Miguel, J. F. S., et al. (2012) · Haematologica · doi:10.3324/haematol.2011.058677 · Cited by 21 · see citing works

Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant

Ceberio, I., Devlin, S. M., Sauter, C. S., Barker, J. N., Castro-Malaspina, H. R., Giralt, S. A., Ponce, D. M., Lechner, L., Maloy, M., Goldberg, J. D., et al. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.930851 · Cited by 20 · see citing works

mTOR inhibitors in advanced renal cell carcinomas: From biology to clinical practice

Barthélémy, P., Hoch, B., Chevreau, C., Joly, F., Laguerre, B., Lokiec, F. M., & Duclos, B. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.02.006 · Cited by 18 · see citing works

Effect of mTORC 1/ mTORC 2 inhibition on T cell function: potential role in graft‐versus‐host disease control

Herrero‐Sánchez, M. C., Rodríguez‐Serrano, C., Almeida, J., San‐Segundo, L., Inogés, S., Santos-Briz, A. J., Briñón, J. G., Miguel, J. F. S., del Cañizo, C., & Blanco, B. (2016) · British Journal of Haematology · doi:10.1111/bjh.13984 · Cited by 18 · see citing works

Medical treatment of neuroendocrine tumours

Weber, H. C. (2013) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32835c034f · Cited by 15 · see citing works

Aberrant germinal center formation, follicular T-helper cells, and germinal center B-cells were involved in chronic graft-versus-host disease

Shao, L., Lie, A. K. W., Zhang, Y., Wong, C.-H., & Kwong, Y. (2015) · Annals of Hematology · doi:10.1007/s00277-015-2394-z · Cited by 14 · see citing works

Future perspectives for mTOR inhibitors in renal cell cancer treatment

Czarnecka, A. M., Kornakiewicz, A., Lian, F., & Szczylik, C. A. (2015) · Future Oncology · doi:10.2217/fon.14.303 · Cited by 14 · see citing works

Everolimus in Combination with Cyclosporin A as Pre- and Posttransplantation Immunosuppressive Therapy in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation

Junghanß, C., Rathsack, S., Wacke, R., Weirich, V., Vogel, H., Drewelow, B., Mueller, S., Altmann, S., Freund, M., & Lange, S. (2011) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2011.12.522 · Cited by 14 · see citing works

Everolimus in Combination with Mycophenolate Mofetil as Pre- and Post-Transplantation Immunosuppression after Nonmyeloablative Hematopoietic Stem Cell Transplantation in Canine Littermates

Machka, C., Lange, S., Werner, J., Wacke, R., Killian, D., Knueppel, A., Knuebel, G., Vogel, H., Lindner, I., Roolf, C., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.06.004 · Cited by 13 · see citing works

GVHD prophylaxis with sirolimus-tacrolimus may overcome the deleterious effect on survival of HLA mismatch after reduced-intensity conditioning allo-SCT

Parody, R., López‐Corral, L., Godino, O. L., Cadenas, I. G., Martínez, A. P., Vázquez, L., Martino, R., Martı́nez, C., Solano, C., Barba, P., et al. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.220 · Cited by 11 · see citing works

Improvement of quality of life in patients with steroid‐refractory chronic graft‐versus‐host disease treated with the mTOR inhibitor everolimus

Lutz, M., Kapp, M., Einsele, H., Grigoleit, G. U., & Mielke, S. (2014) · Clinical Transplantation · doi:10.1111/ctr.12472 · Cited by 11 · see citing works

Quality of life associated with sirolimus for prevention of graft-versus-host disease: results from a randomized trial

Jim, H., Barata, A., Small, B. J., Jacobsen, P. B., & Pidala, J. (2013) · Haematologica · doi:10.3324/haematol.2013.088781 · Cited by 9 · see citing works

Current state of mTOR targeting in human breast cancer.

Wazir, U., Wazir, A., Khanzada, Z. S., Jiang, W. G., Sharma, A. K., & Mokbel, K. (2014) · PubMed · Cited by 9 · see citing works

High Overall Response Rate in Calcineurin Inhibitor-Free Treatment with the mTOR Inhibitor Everolimus in Advanced Extensive Chronic GvHD after Allogeneic Stem Cell Transplantation.

Klink, A., Schilling, K., Rapp, K., Höffken, K., & Sayer, H. G. (2008) · Blood · doi:10.1182/blood.v112.11.2210.2210 · Cited by 9 · see citing works

Wundheilungsstörung bei kutaner Graft-versus-Host-Disease unter Therapie mit Everolimus

Brown, A. J., Neumayer, D., Rafieé-Tari, Z., Krieg, T. M., & Eming, S. A. (2014) · Der Hautarzt · doi:10.1007/s00105-014-2762-y · Cited by 6 · see citing works

A dedicated GvHD clinic may improve the quality of life for allogeneic stem cell transplant survivors

Dignan, F. L., Manwani, R., Potter, M. N., Ethell, M. E., Leonard, H., Brennan, J., Baker, J., & Shaw, B. E. (2012) · Clinical Transplantation · doi:10.1111/ctr.12051 · Cited by 6 · see citing works

Treatment of newly diagnosed moderate or severe chronic graft-versus-host disease with prednisone and everolimus (PredEver first): a prospective multicenter phase IIA study

Ayuk, F. A., Wagner-Drouet, E., Wolff, D., von Hünerbein, N., von Pein, U., Klyuchnikov, E., von Harsdorf, S., Koenecke, C., Sayer, H. G., & Kröger, N. M. (2024) · Bone Marrow Transplantation · doi:10.1038/s41409-024-02289-0 · Cited by 4 · see citing works

Recent advances and limitations of mTOR inhibitors in the treatment of cancer

Ali, E. S., Mitra, K., Akter, S., Ramproshad, S., Mondal, B., Khan, I. N., Islam, M. T., Sharifi‐Rad, J., Călina, D. C., & Cho, W. C. S. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02706-8 · Cited by 213 · see citing works

Autophagy and ALS: mechanistic insights and therapeutic implications

Chua, J. P., De Calbiac, H., Kabashi, E., & Barmada, S. J. (2022) · Autophagy · doi:10.1080/15548627.2021.1926656 · Cited by 189 · see citing works

Tregopathies: Monogenic diseases resulting in regulatory T-cell deficiency

Cepika, A., Sato, Y., Liu, J. M.-H., Uyeda, M. J., Bacchetta, R., & Roncarolo, M. G. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.10.026 · Cited by 139 · see citing works

New and emerging therapies for acute and chronic graft versus host disease

Hill, L. C., Alousi, A. M., Kebriaei, P., Mehta, R. S., Rezvani, K., & Shpall, E. J. (2017) · Therapeutic Advances in Hematology · doi:10.1177/2040620717741860 · Cited by 116 · see citing works

Drug discovery targeting the mTOR pathway

Martelli, A. M., Buontempo, F., & McCubrey, J. A. (2018) · Clinical Science · doi:10.1042/cs20171158 · Cited by 76 · see citing works

Distinct Regulatory and Effector T Cell Metabolic Demands during Graft-Versus-Host Disease

Hippen, K. L., Aguilar, E. G., Rhee, S. Y., Bolivar-Wagers, S., & Blazar, B. R. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.11.005 · Cited by 44 · see citing works

Chronic graft‐versus‐host disease: Current management paradigm and future perspectives

Mawardi, H. H., Hashmi, S. K., Elad, S., Aljurf, M. D., & Treister, N. S. (2018) · Oral Diseases · doi:10.1111/odi.12936 · Cited by 37 · see citing works

The Akt–mTOR network at the interface of hematopoietic stem cell homeostasis

Wu, F., Chen, Z., Liu, J., & Hou, Y. (2021) · Experimental Hematology · doi:10.1016/j.exphem.2021.08.009 · Cited by 35 · see citing works

Myotubularin-related phosphatase 5 is a critical determinant of autophagy in neurons

Chua, J. P., Bedi, K., Paulsen, M. T., Ljungman, M. E., Tank, E. M. H., Kim, E. S., McBride, J. P., Colon, J., Ward, M. E., Weisman, L. S., et al. (2022) · Current Biology · doi:10.1016/j.cub.2022.04.053 · Cited by 25 · see citing works

Loss of immune homeostasis dictates SHIV rebound after stem-cell transplantation

Peterson, C. W., Benne, C., Polacino, P. S., Kaur, J., McAllister, C. E., Filali-Mouhim, A., Obenza, W., Pecor, T., Huang, M.-L. W., Baldessari, A. E., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.91230 · Cited by 28 · see citing works

Endothelial mTOR maintains hematopoiesis during aging

Ramalingam, P., Poulos, M. G., Gutkin, M. C., Katsnelson, L., Freire, A. G., Lazzari, E., & Butler, J. M. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20191212 · Cited by 27 · see citing works

BK virus infection in allogeneic hematopoietic cell transplantation: An update on pathogenesis, immune responses, diagnosis and treatments

Saade, A., Styczyński, J., & Cesaro, S. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.06.009 · Cited by 27 · see citing works

Comprehensive analysis of the immunomodulatory effects of rapamycin on human T cells in graft-versus-host disease prophylaxis

Ehx, G., Ritacco, C., Hannon, M., Dubois, S., Delens, L., Willems, É., Servais, S., Drion, P. V., Beguin, Y. P., & Baron, F. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16505 · Cited by 24 · see citing works

Metabolic Targets for Improvement of Allogeneic Hematopoietic Stem Cell Transplantation and Graft-vs.-Host Disease

Tijaro-Ovalle, N. M., Karantanos, T., Wang, H.-T., & Boussiotis, V. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00295 · Cited by 24 · see citing works

Metabolic Pathways in Alloreactive T Cells

Brown, R., & Byersdorfer, C. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01517 · Cited by 17 · see citing works

Metabolic regulation of Th17 and Treg cell balance by the mTOR signaling

Wang, Z., Xu, Z., Zong, M., & Fan, L. (2025) · Metabolism Open · doi:10.1016/j.metop.2025.100369 · Cited by 18 · see citing works

Rapamycin-based graft-versus-host disease prophylaxis increases the immunosuppressivity of myeloid-derived suppressor cells without affecting T cells and anti-tumor cytotoxicity

Scheurer, J., Reisser, T., Leithäuser, F., Messmann, J. J., Holzmann, K., Debatin, K., & Strauß, G. (2020) · Clinical & Experimental Immunology · doi:10.1111/cei.13496 · Cited by 17 · see citing works

Medical Aspects of mTOR Inhibition in Kidney Transplantation

Cuadrado-Payán, E., Diekmann, F., & Cucchiari, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147707 · Cited by 14 · see citing works

Exosomes, MDSCs and Tregs: A new frontier for GVHD prevention and treatment

Hess, N. J., Kink, J. A., & Hematti, P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1143381 · Cited by 13 · see citing works

Deletion of AMPK minimizes graft-versus-host disease through an early impact on effector donor T cells

Monlish, D. A., Beezhold, K., Chiaranunt, P., Paz, K. G., Moore, N. J., Dobbs, A. K., Brown, R., Ozolek, J. A., Blazar, B. R., & Byersdorfer, C. A. (2021) · JCI Insight · doi:10.1172/jci.insight.143811 · Cited by 11 · see citing works

Low dose PD ‐1 inhibition in relapsed refractory Hodgkin lymphoma after allogeneic stem cell transplant with concomitant active GVHD

Minson, A. G., Douglas, G., Bilmon, I., & Grigg, A. (2018) · British Journal of Haematology · doi:10.1111/bjh.15186 · Cited by 10 · see citing works

T-Cell Metabolism in Graft Versus Host Disease

Karl, F., Hudecek, M., Berberich‐Siebelt, F., Mackensen, A., & Mougiakakos, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.760008 · Cited by 10 · see citing works

A Possible Reason to Induce Acute Graft-vs.-Host Disease After Hematopoietic Stem Cell Transplantation: Lack of Sirtuin-1 in CD4+ T Cells

Xu, Y., Chen, F., Chen, Y., Fu, B., Liu, E., Zou, L., & Liu, L.-X. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03078 · Cited by 6 · see citing works

Mechanistic target of rapamycin modulation: an emerging therapeutic approach in a wide variety of disease processes

Ferro, A. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13117 · Cited by 5 · see citing works

Excretion of Ascaris lumbricoides following reduced‐intensity allogeneic hematopoietic stem cell transplantation and consecutive treatment with mebendazole

Luber, V., Lutz, M., Abele‐Horn, M., Einsele, H., Grigoleit, G. U., & Mielke, S. (2019) · Transplant Infectious Disease · doi:10.1111/tid.13224 · Cited by 3 · see citing works

Effect of mTOR Inhibition with Sirolimus on Natural Killer Cell Reconstitution in Allogeneic Stem Cell Transplantation

Haroun-Izquierdo, A., Lanuza, P. M., Pfefferle, A., Netskar, H., Ask, E. H., Törlén, J., Björklund, A. T., Sohlberg, E., & Malmberg, K. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.03.023 · Cited by 2 · see citing works

Age-related modifications of macrophages influenced by “inflammageing” in graft vs. host disease

Hong, Y., Wan, B., & Li, X. (2020) · Biocell · doi:10.32604/biocell.2020.08887 · Cited by 2 · see citing works

Inflammation-induced tissue damage mimicking GvHD in human skin models as test-platform for immunotherapeutics

Wallstabe, J. (2020) · ALTEX · doi:10.14573/altex.1907181 · Cited by 1 · see citing works

Chronic graft-versus-host disease: focusing on the B cells

Parkhideh, S., Hajifathali, A., Roshandel, E., Bentolhoda, Dehaghi, K., & Soleimani, M. (2021) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs211551582

Hematopoietic Stem Cell Transplantation in Patients with Inborn Errors of Immunity and Malignancy

Gennery, A. R., & Slatter, M. A. (2022) · Interdisciplinary cancer research · doi:10.1007/16833_2022_50

Ovarian toxicity of targeted and immunotherapy in pediatric female patients with oncological diseases

Melnikov, M. E., Дробинцева, А. О., Savelieva, O. E., Lyapunova, L. S., Кондратьев, Г. В., & Kulyova, S. A. (2026) · Advances in molecular oncology · doi:10.17650/2313-805x-2026-13-2-37-48

In Vitro and In Vivo Sirolimus for Modulation of Allogeneic Hematopoietic Stem Cell Transplantation

Fowler, D., & Gress, R. E. (2005) · Current Medicinal Chemistry - Immunology Endocrine & Metabolic Agents · doi:10.2174/156801305774962132

Mammalian target of rapamycin inhibitors as the treatment for steroid‑refractory acute graft‑vs.‑host disease after allogeneic hematopoietic stem cell transplantation: A systematic review and individual patient data meta‑analysis

Guo, Y., Li, Z., Zhang, Y., Pan, Z., Sun, J., Zhang, Y., Chang, S., & Guo, Z. (2025) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2025.13031 · Cited by 1 · see citing works

Survival Benefit from mTOR Inhibition in Lymphoma

Williams, M. E. (2009) · Journal watch · doi:10.1056/oh200901130000002

Long Term Follow-up of Patients Treated with mTOR Inhibitors for Severe Chronic Gvhd Following Allogeneic Stem Cell Transplantation.

Schleuning, M., Judith, D., Burlakova, I., Jedlickova, Z., Heshmat, M., Baurmann, H., & Schwerdtfeger, R. (2009) · Blood · doi:10.1182/blood.v114.22.2254.2254

[Research Progress on the Roles of Rapamycin for the Prophylaxis and Treatment of Graft-Versus-Host Disease --Review].

Wang, D., Wei, J., Feng, Y., & Zhang, X. (2024) · PubMed · doi:10.19746/j.cnki.issn.1009-2137.2024.01.049